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Objectives The objective was to evaluate the pharmacodynamic response of switching patients on maintenance phase clo-
pidogrel therapy after an acute coronary syndrome (ACS) to prasugrel.
Background Prasugrel P2Y12 receptor blockade is associated with greater pharmacodynamic platelet inhibition and reduction
of ischemic complications compared with that of clopidogrel in ACS patients undergoing percutaneous coronary
intervention. The pharmacodynamic effects of switching patients during maintenance phase clopidogrel therapy
after an ACS event to prasugrel are unknown.
Methods The SWAP (SWitching Anti Platelet) study was a phase 2, multicenter, randomized, double-blind, double-dummy,
active-control trial. After a run-in of daily open-label clopidogrel 75 mg with aspirin therapy for 10 to 14 days,
patients were randomly assigned to 1 of the following 3 treatments: placebo loading dose (LD)/clopidogrel
75 mg maintenance dose (MD), placebo LD/prasugrel 10 mg MD, or prasugrel 60 mg LD/10 mg MD. Platelet
function was evaluated at 2 h, 24 h, 7 days, and 14 days using light transmittance aggregometry, VerifyNow
P2Y12 assay, and vasodilator-stimulated phosphoprotein phosphorylation.
Results A total of 139 patients were randomized, of whom 100 were eligible for analysis. Maximum adenosine
diphosphate-induced platelet aggregation (20 M) by light transmittance aggregometry at 1 week (primary end
point) was lower after prasugrel MD compared with clopidogrel MD (41.1% vs. 55.0%, p  0.0001), and was
also lower in the prasugrel LDMD group compared with clopidogrel MD (41.0% vs. 55.0%, p  0.0001). At 2 h,
a prasugrel LD resulted in higher platelet inhibition compared with the other regimens. Similar results were
found using light transmittance aggregometry with 5 M adenosine diphosphate, VerifyNow P2Y12, and
vasodilator-stimulated phosphoprotein phosphorylation assays.
Conclusions For patients receiving maintenance clopidogrel therapy after an ACS event, switching from clopidogrel to prasug-
rel is associated with a further reduction in platelet function by 1 week using prasugrel MD or within 2 h with the
administration of a prasugrel LD. (A Pharmacodynamic Comparison of Prasugrel [LY640315] Versus Clopidogrel
in Subjects With Acute Coronary Syndrome Who Are Receiving Clopidogrel [SWAP]; NCT00356135) (J Am Coll
Cardiol 2010;56:1017–23) © 2010 by the American College of Cardiology Foundation
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Results of the SWAP Study September 21, 2010:1017–23Current guidelines recommend a
combination of aspirin and a
thienopyridine for the prevention
of recurrent ischemic events in
patients with acute coronary syn-
dromes (ACS) and for patients
undergoing percutaneous coro-
nary intervention (PCI) (1).
Variable antiplatelet response to
clopidogrel has been reported,
and patients with a reduced effect
have an increased risk of isch-
emic complications (2). Prasugrel
inhibits platelet activation through
irreversible P2Y12 receptor block-
ade by a mechanism similar to
that of clopidogrel (3). Pharma-
codynamic studies have shown
that prasugrel exerts greater and
more consistent platelet inhibi-
tion than clopidogrel even when
used at high doses (4). In pa-
ients with ACS undergoing PCI, prasugrel resulted in
ower recurrent atherothrombotic event rates but more
ajor bleeding compared with clopidogrel (5). Neverthe-
ess, there was a significant net clinical benefit, defined as the
omposite of efficacy and bleeding end points, with prasugrel.
urther, patients randomly assigned to clopidogrel who sur-
ived their first event had a higher risk of recurrent events,
ncluding cardiovascular mortality, compared with prasugrel
atients (6). Prasugrel is approved for the reduction of throm-
otic cardiovascular events in patients with ACS managed with
CI. Therefore, switching these patients at high risk for
ecurrent cardiovascular events from clopidogrel to prasugrel
ay be a consideration, particularly if they respond poorly to
lopidogrel by platelet function (2) or genomics testing (7), or
re subject to reported drug–drug interactions that hamper the
ffectiveness of clopidogrel (8). However, the pharmacody-
amic effects of changing from clopidogrel to prasugrel therapy
n patients who had an ACS event are largely unknown.
ethods
tudy design. The SWAP (SWitching Anti Platelet) study
as a phase 2, multicenter, randomized, double-blind,
edtronic, and Eli Lilly; and grant support, consulting fees, and honoraria from
chering-Plough. Dr. Frelinger reports grant and research support from Bristol-
yers Squibb, Sanofi-Aventis, Eli Lilly, Daiichi Sankyo, and GLSynthesis; and
onsulting fees from Eli Lilly. Dr. Gurbel reports receiving honoraria for lectures from
anofi-Aventis, AstraZeneca, Eli Lilly, Daiichi Sankyo, and Schering-Plough;
onsulting fees from Schering-Plough, AstraZeneca, Portola, Haemoscope, Sanofi,
ozen, and Bayer; and grant and research support from Schering-Plough, AstraZeneca,
ortola, Haemoscope, and Bayer. Drs. Costigan, Jakubowski, Ojeh, and Effron are
mployees of and report equity ownership of or stock options in Eli Lilly. All other
uthors have reported that they have no relationships to disclose.
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
ADP  adenosine
diphosphate
LD  loading dose
LTA  light transmittance
aggregometry
MD  maintenance dose
MPA  maximum platelet
aggregation
PCI  percutaneous
coronary intervention
PRU  P2Y12 reaction
units
VASP-P  vasodilator-
stimulated phosphoprotein
phosphorylation
VN  VerifyNowManuscript received November 16, 2009; revised manuscript received February 5,
010, accepted February 9, 2010.ouble-dummy, active-control trial designed to evaluate the
harmacodynamic response in patients on maintenance
ose (MD) clopidogrel therapy after an ACS event who
ere switched to prasugrel MD, with or without a prasugrel
oading dose (LD). Patients were eligible for the study if
hey were between 18 and 75 years of age, 30 to 330 days
fter an ACS event, and treated with daily aspirin and
lopidogrel. Patients were excluded in the presence of any of
he following: cardiogenic shock, refractory ventricular ar-
hythmias, congestive heart failure (class III and IV), or left
ain coronary artery stent; had a planned PCI or coronary
rtery bypass graft surgery to occur during the study; or had
ndergone PCI or coronary artery bypass graft surgery
ithin 30 days of study entry. Patients were also excluded if
hey were at high risk of bleeding, including a history of
schemic or hemorrhagic stroke, intracranial neoplasm, ar-
eriovenous malformation or aneurysm, a history of tran-
ient ischemic attack, or a body weight 60 kg.
The study design is illustrated in Figure 1. Patients
eceived a run-in of open-label 75 mg clopidogrel taken
aily with their usual dose of aspirin for 10 to 14 days to
ssess compliance before randomization and to confirm a
teady-state level of clopidogrel pharmacodynamic effects.
atients were then randomly assigned and switched 24 
h after the last dose of clopidogrel to 1 of 3 study arms:
lacebo LD/clopidogrel 75 mg MD (clopidogrel MD),
lacebo LD/prasugrel 10 mg MD (prasugrel MD), or 60
g prasugrel LD/prasugrel 10 mg MD (prasugrel
DMD). Clopidogrel (open-label and blinded study
rug) was commercially available clopidogrel bisulfate (Pla-
ix, 75 mg tablets, Bristol-Myers Squibb/Sanofi-Aventis,
ew York, New York). Prasugrel was administered as
ablets containing 10 mg prasugrel (Eli Lilly and Company,
ndianapolis, Indiana). The MD phase continued for 13 to
5 days. Aspirin was maintained using a dose at the
iscretion of the investigator (81 to 325 mg/day) and
emained unchanged throughout the study.
Figure 1 Study Design
ACS  acute coronary syndrome; LD  loading dose; MD  maintenance dose.
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September 21, 2010:1017–23 Results of the SWAP StudyPlatelet function was tested at 6 time points: before study
ntry, 24 h after the last dose of clopidogrel from the run-in
hase, 2 and 24 h after LD, and 1 and 2 weeks after
andomization (approximately 24 h after the prior MD for
he indicated day to avoid any potential interference in the
ssays). Platelet function measures included 1) maximum
latelet aggregation (MPA) after stimulation with 5 and
0 M adenosine diphosphate (ADP) using light transmit-
ance aggregometry (LTA); 2) P2Y12 reactivity index, de-
ermined by vasodilator-stimulated phosphoprotein phosphor-
lation (VASP-P) using quantitative flow cytometry and
ommercially available labeled monoclonal antibodies (Biocy-
ex, Marseille, France) at a central laboratory (Sinai Center for
hrombosis Research, Baltimore, Maryland); and 3) P2Y12
eaction units (PRU) determined by VerifyNow P2Y12 (VN-
2Y12, Accumetrics, San Diego, California). Platelet function
ssessments were performed according to standard protocols
nd are described in detail elsewhere (9,10).
The protocol was approved by the institutional review
oards at the individual sites and the study was conducted in
ccordance with regulatory standards and good clinical
ractice guidelines rooted in the Declaration of Helsinki.
ll patients provided written informed consent. The au-
hors had full access to the data, take full responsibility for
ts integrity, and have agreed to the manuscript as written.
tudy end points and statistical analyses. The primary
nd point was the comparison of mean MPA to 20 M
DP at 1 week (7 to 9 days after randomization) of
rasugrel MD to clopidogrel MD. This was performed by
omparing the least square means of prasugrel MD group to
lopidogrel MD group, obtained from an analysis of covari-
nce model applied to the 3 randomized treatments groups.
n this model, treatment and study site were fixed effects,
nd the latest MPA measurement before randomization
after 10 to 14 days of open-label clopidogrel 75 mg MD
nd aspirin) was a covariate. Similar comparisons were also
erformed for the other treatment comparisons (prasugrel
DMD vs. clopidogrel MD; prasugrel LDMD vs.
rasugrel MD). A similar analysis was performed in which
he 2 prasugrel groups were combined and compared with
he clopidogrel MD group at day 7. The primary analysis
opulation was the pharmacodynamic population: all ran-
omized patients who had evaluable MPA at the 7-day
isit, took at least 80% of their doses through week 1, and
ad the last dose of study drug the day before the blood
raw for MPA. Additionally, MPA to 20 M ADP was
nalyzed by a linear mixed effect model with treatment,
ategorical time point, and time-by-treatment interaction as
xed effects, subject as a random effect, and MPA before
andomization as a covariate, with an unstructured covari-
nce structure. Enrollment of as many as 150 patients to
each 120 patients completing the study was allowed.
econdary end points included functional assessments at all
ther time points by means of LTA as well as PRI and
N-P2Y12 using similar statistical analyses. 7Data related to safety and tolerability of switching pa-
ients from clopidogrel to prasugrel therapy were collected
rom patients who took at least 1 dose of randomized study
rug. This information was assessed by evaluating vital
igns, bleeding, and all reported adverse events. Bleeding
as classified as minimal, minor, or major according to the
IMI (Thrombolysis In Myocardial Infarction) criteria (5).
reatment-emergent adverse events were summarized using
he Medical Dictionary for Regulatory Activities (11) pre-
erred term. For continuous characteristics, means of the
reatment groups were compared using analysis of covari-
nce. For categorical characteristics, percents were com-
ared by chi-square tests. Statistical analysis was performed
sing SAS version 9.1 (SAS Institute, Cary, North Caro-
ina). Tests of treatment effects were conducted at 2-sided
lpha level of 0.05 without adjustment for multiple
omparisons.
esults
atient population. From July 2006 through December
008, 159 patients were enrolled (see Online Appendix for
articipating centers). Of these, 20 patients failed to com-
lete the run-in phase. The safety population included a
otal of 139 randomized patients. A total of 128 patients
ompleted the study, of whom 100 had evaluable data at
oth baseline and 7-day follow-up and made up the phar-
acodynamic population to assess the primary end point.
igure 2 describes the patient disposition. Demographics
nd baseline characteristics for the pharmacodynamic pop-
lation are summarized in Table 1, and show no significant
ifferences among the 3 treatment groups.
harmacodynamic evaluations. After the run-in phase
ith open-label clopidogrel, MPA (20 M ADP) was
3.8%, 60.2%, and 55.5% in the patients randomly allocated
o clopidogrel MD, prasugrel MD, and prasugrel LDMD
reatment, respectively. The MPA (20 M ADP) at day 7
fter switching to study drug was significantly lower after
rasugrel MD compared with clopidogrel MD (41.1% vs.
5.0%, p  0.0001), as well as in the prasugrel LDMD
roup compared with clopidogrel MD (41.0% vs. 55.0%,
 0.0001) (Fig. 3A). As the MPA for each prasugrel
roup was essentially the same by day 7 after switching, the
groups were pooled, and the combined prasugrel group
emonstrated a lower MPA compared with clopidogrel
D (41.1% vs. 55.0%, p  0.0001). Reduced platelet
ggregation was seen at 2 h after switching from open-label
lopidogrel 75 mg to prasugrel LDMD compared with
ither clopidogrel MD or prasugrel MD. This difference
as sustained to 24 h. Additionally, there was a small but
ignificant reduction in platelet aggregation at 2 h by both
lopidogrel MD and prasugrel MD compared with their
espective baselines. This reduction remained significant for
rasugrel MD by 24 h but not for clopidogrel MD. By
days in the prasugrel LDMD group, the MPA to MD
w
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Results of the SWAP Study September 21, 2010:1017–23as higher than seen 24 h after the LD (40.6% vs. 27.4%).
reater decreases in MPA (20 M ADP) in the prasugrel
DMD compared with the clopidogrel MD were ob-
erved at all time points from 2 h to 14 days (p  0.0001,
ll time points). Similar results were obtained using
M ADP as the agonist (Fig. 3B). Switching from
pen-label clopidogrel 75 mg to prasugrel MD alone did
Figure 2 Subject Disposition
aSafety population: all randomized patients who took at least 1 dose of randomize
able maximum platelet aggregation (MPA) at the 7-day visit, took at least 80% of t
blood draw for MPA. ASA  acetyl salicylic acid (aspirin); LD  loading dose; MDot significantly alter the level of platelet aggregation oompared with clopidogrel MD at 2 or 24 h compared
ith continued clopidogrel 75 mg MD (49.5% vs. 48.1% at
h and 52.3% vs. 53.8% at 24 h, respectively). Pharmaco-
ynamic evaluations by the other platelet function assays
VASP-P and VN-P2Y12) were consistent with the LTA
bservations (Figs. 4A and 4B).
afety and tolerability. In the clopidogrel MD group, 52%
y drug. bPharmacodynamic population: all randomized patients who had evalu-
ses through week 1, and had the last dose of study drug the day before the
tenance dose.d stud
heir do
 mainf patients reported at least 1 adverse event whereas 36.2%
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September 21, 2010:1017–23 Results of the SWAP Studyf the prasugrel MD group and 25% of the prasugrel
DMD group reported at least 1 adverse event (p 
.027). The majority of events were mild or moderate in
everity. There were no serious adverse events reported in
ither the clopidogrel MD group or prasugrel LDMD
roup. A serious adverse event was reported in 3 patients in
he prasugrel MD group, and included chest pain (n  1),
n-stent restenosis (n  1), and syncope (n  1). None of
hese events was considered related to the study drug and
id not lead to treatment discontinuation. Bleeding by
IMI criteria was reported in 12.5% of the clopidogrel
5 mg MD group, 8.5% of the prasugrel 10 mg MD group,
nd 13.6% of the prasugrel LDMD group. All bleeding
vents were minimal by TIMI criteria, and none needed
edical or surgical intervention. No clinically significant
ndings were identified through the evaluation of clinical
aboratory tests or vital signs, after switching from clopi-
aseline Demographics and Clinical CharacteristicsTable 1 Baseline Demographics and Clinical Characteristics
Placebo LD,
Clopidogrel 75 mg MD
(n  33)
Age, yrs 57.1 7.1
Male 63.6
Race
Caucasian 60.6
African 27.3
Asian 0
Other 12.1
BMI, kg/m2 33.1 7.0
Risk factors/medical history
Current smoker 21.2
Hypertension 81.8
Hypercholesterolemia 78.1
Diabetes mellitus 33.3
Prior MI 30.3
Prior TIA 3.0
Prior stroke 3.0
Prior PCI 42.4
Prior CABG 12.1
Qualifying ACS event
Time from event to study entry, days 77.4 47.3
Unstable angina/NSTEMI 60.6
STEMI 39.4
BMS (1) placed at time of event 39.4
DES (1) placed at time of event 45.4
Medical therapy
Beta-blockers 90.9
Statins 81.8
Lipophilic 63.6
Nonlipophilic 18.2
Proton-pump inhibitors 36.4
Calcium-channel blockers 15.2
alues aremean SD or %. All patients were receiving aspirin (81 to 325mg/day) and clopidogrel (
n 81 mg daily aspirin dose. The p values were determined using Fisher exact test or by analysis
omparison.
BMI body mass index; BMS bare-metal stent(s); CABG coronary artery bypass graft surge
STEMI  non–ST-segment elevation myocardial infarction; PCI  percutaneous coronary interveogrel to prasugrel. Fiscussion
he SWAP study is the first to assess the pharmacodynam-
cs and tolerability of a prasugrel 10 mg MD administered
mmediately after clopidogrel 75 mg MD with or without a
rasugrel LD to patients on maintenance clopidogrel ther-
py after an ACS event. In particular, the results of the
WAP study show that switching from 75 mg MD clopi-
ogrel to 10 mg MD prasugrel, with or without an LD, in
hese patients results in significantly decreased platelet
unction 1 week later, as measured by multiple assays
ncluding LTA, VASP-P, and VN-P2Y12. Additionally,
witching to 10 mg prasugrel MD without an LD did not
esult in a loss of the existing platelet inhibition resulting
rom maintenance dose clopidogrel for the initial 24 h.
urther, administration of a 60 mg prasugrel LD resulted in
rapid and marked decrease in platelet aggregation by 2 h.
Placebo LD,
Prasugrel 10 mg MD
(n  36)
Prasugrel 60 mg LD,
Prasugrel 10 mg MD
(n  31) p Value
57.3 7.9 57.0 8.6 0.99
77.8 67.7 0.43
0.071*
83.3 83.9
16.7 12.9
0 0
0 3.2
31.0 6.5 31.1 6.1 0.35
41.7 25.8 0.15
80.6 81.8 0.95
88.9 78.1 0.47
36.1 16.1 0.16
36.1 16.1 0.17
2.8 3.2 1.00
0 0 0.64
44.4 32.3 0.58
19.4 6.5 0.32
102.2 77.4 82.1 71.0 0.26
63.9 61.3 0.97†
36.1 38.7
30.6 41.9 0.61
52.8 58.1 0.59
94.4 93.6 0.89
88.9 83.9 0.73
58.3 61.3 0.96
33.3 25.8 0.36
16.7 25.8 0.18
8.3 16.1 0.57
day). During the study, themajority of patients (at least 92.8% of all patients at each visit) received
nce. *Race by treatment comparison. †Acute coronary syndrome (ACS) event type by treatment
 drug-eluting stent(s); LD loading dose; MDmaintenance dose; MImyocardial infarction;
TEMI  ST-segment elevation myocardial infarction; TIA  transient ischemic attack.75mg/
of variainally, switching from clopidogrel to prasugrel was well
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Results of the SWAP Study September 21, 2010:1017–23olerated without major safety events in this study. These
ndings provide pharmacodynamic insights to clinicians
ho may choose to switch from clopidogrel to prasugrel
herapy.
The SWAP study results are consistent with a previous
tudy of healthy volunteers in which switching directly
rom clopidogrel to prasugrel resulted in a significant
eduction in platelet function and was well tolerated (12).
oreover, in a recent study involving ACS patients
witching to a prasugrel 10 mg dose directly after
reatment with a high clopidogrel LD (900 mg) and MD
150 mg) resulted in greater platelet inhibition without
on
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Figure 3 Maximum Platelet Aggregation
(A) Mean maximum platelet aggregation (MPA) to 20 M adenosine diphos-
phate (ADP)  SD. (B) Mean MPA to 5 M ADP  SD. Time 0 is baseline
value obtained after 2-week open-label clopidogrel and before administration of
first dose of study drug. *p  0.0001 versus clopidogrel 75 mg maintenance
dose (MD). †p  0.0001 versus prasugrel 10 mg MD. Blue triangles indicate
placebo loading dose (LD)/clopidogrel 75 mg MD (n  33); green circles indi-
cate placebo LD/prasugrel 10 mg MD (n  36); and green squares indicate
prasugrel 60 mg LD/10 mg MD (n  31).erious or life-threatening bleeding (13). The SWAP rtudy supports that switching directly from clopidogrel to
rasugrel provides additional platelet inhibition, which
an be achieved more rapidly (within 2 h) if an LD of
rasugrel is given. The pharmacodynamic effects are
onsistent with the higher levels of prasugrel active
etabolite achieved after prasugrel administration com-
ared with clopidogrel (3). These results are in contrast
ith those observed when switching from a direct-acting
eversible P2Y12 inhibitor to clopidogrel, which impeded
latelet inhibitory effects of clopidogrel (14).
Lower levels of platelet function, reflecting greater plate-
et inhibition, have been associated with a lower risk of
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Figure 4 Platelet Function Assays
(A) Vasodilator-stimulated phosphoprotein phosphorylation (VASP-P). (B) Verify-
Now (VN) P2Y12. Results are presented as mean VASP-P platelet reactivity
index (PRI)%  SD (A) or mean VN-P2Y12 reaction units (PRU)  SD (B) at
each time point. Time 0 is baseline value obtained after 2 weeks of open-label
clopidogrel and before administration of first dose of study drug. *p  0.0001
versus clopidogrel 75 mg maintenance dose (MD). †p 0.0001 versus prasug-
rel 10 mg MD. Blue triangles indicate placebo loading dose (LD)/clopidogrel
75 mg MD (n  33); green circles indicate placebo LD/prasugrel 10 mg MD
(n  36); and green squares indicate prasugrel 60 mg LD/10 mg MD
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September 21, 2010:1017–23 Results of the SWAP Studyevel of platelet inhibition compared with clopidogrel, there
s no consensus agreement establishing specific levels of
latelet function for optimal clinical efficacy or safety out-
omes. Ongoing large-scale trials are evaluating the link
etween platelet function testing and patient outcomes and
afety, as well as whether more intensive antiplatelet therapy
irected by point-of-care testing using high-dose clopi-
ogrel or prasugrel can improve clinical outcomes.
tudy limitations. The SWAP study was a pharmacody-
amic study and not sized to assess efficacy or safety.
herefore, this study was not designed to determine
hether a reduction in cardiovascular thrombotic events
ould result when switching from clopidogrel to prasugrel.
dditionally, although no serious bleeding was observed, no
onclusions regarding the clinical results can be made.
ltimately, there was no evaluation of switching from
rasugrel to clopidogrel.
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APPENDIX
or a complete list of the investigators and centers participating
n the SWAP study, please see the online version of this article.
